AstraZeneca’s experimental COPD drug tozorakimab cuts flare-ups by 30% in Phase 3 trials

In two Phase 3 studies, AstraZeneca’s injectable COPD candidate tozorakimab reduced the rate of disease exacerbations by roughly 30%, according to data released on Tuesday. The trials measured flare‑ups that require medical attention, such as severe cough or breathlessness, and showed a consistent benefit across the study populations.

The findings position tozorakimab as a potential new treatment option for the large global COPD patient base, a condition that remains under‑served despite being the third‑leading cause of death worldwide. Reducing exacerbations could improve quality of life and lower healthcare utilization for these patients.

Analysts and the company estimate that, if approved, the drug could generate billions of dollars in annual sales, not only for COPD but also for related respiratory diseases such as asthma. The positive readout follows a period of mixed trial outcomes for AstraZeneca, offering a reassuring signal for investors and the broader pharma market.